Please login to the form below

Not currently logged in
Email:
Password:

Aradigm

This page shows the latest Aradigm news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease. ... It paid Aradigm a $5m milestone last September after the

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    The companies have already succeeded where ill-fated programmes from Lilly/Alkermes and Novo Nordisk/Aradigm failed, but it must now prove it can do better than Pfizer's Exubera, launched

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols . ... Licence equity. Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics